DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Brian Cheng - 3 Graves - 1 Cheng - 1 — CNBC's Michael Bloom - 1 J.P - 1 Morgan - 1 drugmakers Johnson - 1 Johnson - 1
Top related locs:
IMVT Immunovant Roche United States York Bengaluru OpenAI's
Top related orgs:
JPMorgan - 2 IMVT - 1 Telavant - 1 Merck - 1 Prometheus - 1 UCB - 1 Roivant Sciences - 1 Thomson - 1

Search resuls for: "Brian Cheng"


6 mentions found


☆ JPMorgan says buy this immunology stock primed to rally nearly 40%
  + stars: | 2024-02-20 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +2 min
Immunovant could emerge as a key player in the autoimmune space, according to JPMorgan. The bank initiated coverage of the biotech stock at an overweight rating, also setting a price target of $51. That implies that shares of Immunovant could rally more than 37% from their Friday closing price of $37.13. Immunovant stock has slid 9% so far this quarter. IMVT YTD mountain IMVT YTD chart As a key catalyst, the analyst underscored Immunovant's stats as one of the key players using anti-neonatal Fc receptor technology, or anti-FcRn technology, to treat autoimmune diseases.
Persons: Brian Cheng, Graves, Cheng, — CNBC's Michael Bloom Organizations: JPMorgan, IMVT, Telavant, Merck, Prometheus Locations: Immunovant, IMVT, Roche
☆ Immunovant shares surge as early antibody treatment data beats expectations
  + stars: | 2023-09-26 | by ( Bhanvi Satija | Thomson Reuters | Bhanvi Satija Reports On Pharmaceutical Companies | ) www.reuters.com   time to read: +2 min
Sept 26 (Reuters) - Shares of Immunovant (IMVT.O) surged nearly 80% on Tuesday, after early-stage data from its experimental antibody treatment exceeded analysts' expectations. Immunovant is developing its antibody drug, IMVT-1402, as an under-the-skin injection to potentially treat autoimmune diseases. Immunovant's experimental drug reduced the levels of IgG, or immunoglobulin antibodies, that cause inflammation and disease in healthy adults. Shares of Roivant Sciences (ROIV.O), Immunovant's largest shareholder with a 56.5% stake, according to LSEG data, also rose 17.5% to $12. The positive data from IMVT-1402 could give Roivant another "potentially blockbuster" candidate to transact, after its experimental treatment for bowel disease, Jefferies analyst Dennis Ding said.
Persons: J.P, Morgan, Brian Cheng, drugmakers Johnson, Johnson, Hytrulo, Immunovant, transact, Jefferies, Dennis Ding, Bhanvi, Krishna Chandra Organizations: UCB, Roivant Sciences, Thomson Locations: United States, York, IMVT, Bengaluru
☆ JPMorgan highlights its top stock picks heading into July
  + stars: | 2023-07-07 | by ( Brian Evans | ) www.cnbc.com   time to read: +2 min
JPMorgan updated its list of top stock picks for July, as investors are now eyeing the second half of the year. To kick off this month, JPMorgan added Domino's Pizza and Dollar General to its focus list. Domino's Pizza stock has slipped more than 3% in 2023, but it's still rated overweight by JPMorgan analyst John Ivankoe. Holdovers from previous iterations of the focus list include tech stocks Amazon and Microsoft . JPMorgan removed multimedia stock Avid Technology from its focus list earlier this week.
Persons: John Ivankoe, Stifel, Brian Cheng, Morgan Stanley Organizations: JPMorgan, Nasdaq, Sciences, Microsoft, Federal Trade Commission, Amazon Prime, Avid Technology Locations: OpenAI's
☆ JPMorgan says this biotech stock could rally 60%
  + stars: | 2023-01-24 | by ( Alex Harring | ) www.cnbc.com   time to read: +2 min
JPMorgan has moved off the sidelines on Allogene Therapeutics , a clinical-stage immuno-oncology company the bank believes could see positive catalysts. Analyst Brian Cheng upgraded the stock to overweight from neutral. Cheng also cut his price target nearly in half to $11 from $20, but the new forecast implies the stock will gain 60.3% over the next year. The CD19 franchise is centered around studies for relapsed or refractory non-Hodgkin lymphoma. The analyst noted that one concern about the company is the state of its BCMA franchise, which is focused on treatments for relapsed and refractory multiple myeloma.
☆ JPMorgan says these 8 energy stocks have huge 'upside potential' amid painful rate hikes – and breaks down 2 others that allows investors to cash in near-term
  + stars: | 2022-11-02 | by ( Morgan Chittum | ) www.businessinsider.com   time to read: +3 min
While the S&P 500 is down nearly 20% year-to-date, its energy sector is up about 60% so far in 2022. JPMorgan recommends these 8 Russell 2000-listed energy stocks amid a harsh macro backdrop. Amid the central bank's monetary tightening to combat near 40-year high inflation, stocks continue their downtrend. Energy stocks, in particular, could be a nice buying opportunity as the US economy appears to be heading toward a recession. With a mix of both growth and value stocks, JPMorgan recommends these 10 Russell 2000-listed stocks amid harsh macro conditions.
☆ These are JPMorgan's favorite stocks heading into November
  + stars: | 2022-11-01 | by ( Tanaya Macheel | ) www.cnbc.com   time to read: +1 min
The firm's Analyst Focus List is a compilation of its analysts' favorite names for various investment strategies, and it gets a refresh every month. Almost all the stocks included have overweight ratings and are recommended for growth or value strategies. For November, the analysts removed a handful of stocks, including First Republic , and added just one: the cancer treatment developer BioAtla . JPMorgan included the stock for a near-term strategy and put a $23 price target on it. McDonald's , Allstate , AbbVie and Qualcomm are among the value stocks that are in the mix.
0 next >>
Total: 6